Thermo Fisher completes the Acquisition of Patheon

There’s a lot going on here at Kastner Labs that we’d like to share with you. Find a variety of articles on case studies, open days and much more below.

Thermo Fisher completes the Acquisition of Patheon

Thermo Fisher completes the Acquisition of Patheon

Posted on the September 4th, 2017

The range of services that Patheon offer for drug substances and drug products is wider than that of any other CDMO. They offer end-to-end capabilities and expertise to take a drug discovery from pre-clinical and clinical development, through scale-up, all the way to commercial supply. The Swindon facility houses both the production and packaging facility and the laboratories for product development and quality control.
On May 15, 2017, Thermo Fisher Scientific announced plans to purchase Patheon for $35 per share in cash.
Patheon has a network of facilities, primarily in North America and Europe, and approximately 9000 professionals worldwide. In 2016, Patheon generated approximately $1.9 billion in revenue and will become part of Thermo Fisher’s Laboratory Products and Services Segment, the companies said in a press release about the acquisition.
“The combined company’s extensive and deep relationships in the biopharma industry will enable significant cross-selling opportunities,” the companies noted in a statement. “For example, having biologics development and manufacturing capabilities as well as bioproduction technologies in one company will allow Thermo Fisher to offer a more comprehensive portfolio to gain share with these customers.”
On Aug. 29, 2017, Thermo Fisher Scientific announced its completed acquisition of Patheon, a contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. The close follows the company’s initial offer for Patheon at $35 per share in cash.
“We’re pleased to complete our acquisition of Patheon and look forward to the significant value this transaction will create for our customers and our shareholders,” said Marc Casper, CEO and president of Thermo Fisher Scientific, in a company press release. “By adding Patheon’s highly complementary CDMO capabilities to our leading clinical trials services and bioproduction technologies, we will be an even stronger partner for our pharmaceutical and biotech customers. We’re delighted to welcome our Patheon colleagues to the Thermo Fisher team and excited about the new opportunities we have to help our customers accelerate innovation and enhance productivity by leveraging our combined strengths.”
Kastner were recently invited to quote for the replacement of laboratory furniture and fume cupboards on several floors of the facility in Swindon. There is currently significant investment going into the Swindon site.